Physician profile
Joseph Tripodi
NPI 1982607081
$4,270.91
in general payments reported to CMS, 2019-2025
27 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $119 · 2021: $325 · 2022: $334 · 2023: $194 · 2024: $331 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $524.68 | 2025 | General - Hemostasis, General - Polypectomy, Exalt Model D |
| Ethicon US, LLC | $476.24 | 2019-2021 | |
| Abbvie INC. | $395.81 | 2022-2025 | |
| Janssen Biotech, INC. | $319.03 | 2021-2025 | Tremfya, Stelara |
| Medtronic, INC. | $297.61 | 2022-2025 | Signia |
| Braintree Laboratories, INC. | $214.35 | 2019-2025 | Sutab, Suflave |
| Capsovision, INC. | $200.34 | 2025 | Capsocam Plus |
| Ardelyx, INC. | $173.78 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.77 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $147.53 | 2025 | Dupixent |
| Steris Corporation | $145.30 | 2025 | |
| Novo Nordisk INC | $138.84 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $137.29 | 2023 | Terlivaz |
| 3-D Matrix, INC. | $128.89 | 2024 | |
| Janssen Scientific Affairs, LLC | $119.34 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $110.07 | 2025 | |
| Celgene Corporation | $85.59 | 2021-2022 | |
| Pfizer INC. | $83.16 | 2025 | |
| Genzyme Corporation | $80.84 | 2025 | |
| Lucid Diagnostics INC. | $73.65 | 2021 | |
| Phathom Pharmaceuticals, INC. | $70.07 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $57.04 | 2023 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $33.89 | 2025 | Entyvio |
| Madrigal Pharmaceuticals | $30.77 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.13 | 2025 | Rebyota |
| Olympus America INC. | $14.20 | 2025 | Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Tripodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.